Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells $66,120.00 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) Director Michael Garnreiter sold 87 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $760.00, for a total transaction of $66,120.00. Following the sale, the director now owns 24,653 shares in the company, valued at approximately $18,736,280. This represents a 0.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Garnreiter also recently made the following trade(s):

• On Wednesday, June 4th, Michael Garnreiter sold 5,913 shares of Axon Enterprise stock. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00.

Axon Enterprise Price Performance

AXON traded up $7.88 on Friday, reaching $796.24. 210,754 shares of the company's stock were exchanged, compared to its average volume of 729,301. Axon Enterprise, Inc. has a twelve month low of $278.24 and a twelve month high of $798.16. The stock has a market cap of $61.99 billion, a PE ratio of 205.75, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock's fifty day moving average price is $638.88 and its 200-day moving average price is $615.19.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same period in the prior year, the business earned $1.15 earnings per share. The business's revenue was up 31.3% compared to the same quarter last year. Sell-side analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Analyst Ratings Changes

AXON has been the topic of a number of recent analyst reports. Bank of America increased their price target on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday. Needham & Company LLC increased their target price on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. The Goldman Sachs Group boosted their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday, May 14th. Northcoast Research cut shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. Finally, Barclays lifted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise presently has a consensus rating of "Moderate Buy" and an average price target of $699.55.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds have recently modified their holdings of AXON. Brighton Jones LLC purchased a new stake in shares of Axon Enterprise in the 4th quarter valued at approximately $480,000. Caprock Group LLC acquired a new stake in Axon Enterprise during the fourth quarter worth $329,000. DAVENPORT & Co LLC increased its stake in Axon Enterprise by 7.6% during the fourth quarter. DAVENPORT & Co LLC now owns 894 shares of the biotechnology company's stock worth $531,000 after acquiring an additional 63 shares during the last quarter. U.S. Capital Wealth Advisors LLC raised its position in Axon Enterprise by 53.2% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 2,032 shares of the biotechnology company's stock valued at $1,208,000 after purchasing an additional 706 shares during the period. Finally, GPS Wealth Strategies Group LLC lifted its stake in shares of Axon Enterprise by 74.1% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.